Lv1
36 积分 2023-12-07 加入
An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma
3个月前
已完结
Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering
3个月前
已完结
Polyplex of peptide-mannan and RNA for intranasal delivery of TGF-β siRNA in treatment of pulmonary fibrosis
4个月前
已完结
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias
4个月前
已完结
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
4个月前
已完结
CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer
5个月前
已完结
A second-generation M1-polarized CAR macrophage with antitumor efficacy
5个月前
已完结
104 Development and characterization of human chimeric antigen receptor monocytes (CAR-Mono), a novel cell therapy platform
5个月前
已完结
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
5个月前
已完结
A second-generation M1-polarized CAR macrophage with antitumor efficacy
5个月前
已完结
皖公网安备34019202002308
